uniqure biopharma b.v. - alipogene tiparvovec - hyperlipoproteinemia type i - lipid modifying agents - glybera is indicated for adult patients diagnosed with familial lipoprotein lipase deficiency (lpld) and suffering from severe or multiple pancreatitis attacks despite dietary fat restrictions. the diagnosis of lpld has to be confirmed by genetic testing. the indication is restricted to patients with detectable levels of lpl protein.
European Union -
English -
EMA (European Medicines Agency)